Trial Profile
A Phase II Randomized Study of Ixabepilone vs. Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2/Neu-Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2022
Price :
$35
*
At a glance
- Drugs Ixabepilone (Primary) ; Antineoplastics
- Indications Early breast cancer
- Focus Therapeutic Use
- 10 Mar 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
- 10 Mar 2022 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2024.
- 09 Mar 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.